Literature DB >> 29181527

Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor.

Michael D Shapiro1, Joshua Miles1, Hagai Tavori1, Sergio Fazio1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29181527     DOI： 10.7326/M17-2485

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  13 in total

Review 1.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

2.  Evaluation of the Effectiveness and Safety of Alirocumab Use in Statin-Intolerant Veterans.

Authors:  Fiona I Imarhia; Elisabeth M Sulaica; Tyler Varisco; Marcy Pilate
Journal:  Fed Pract       Date:  2021-11

3.  Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity.

Authors:  Jae Hyun Byun; Paul F Lebeau; Khrystyna Platko; Rachel E Carlisle; Mahi Faiyaz; Jack Chen; Melissa E MacDonald; Yumna Makda; Tamana Yousof; Edward G Lynn; Jeffrey G Dickhout; Joan C Krepinsky; Fiona Weaver; Suleiman A Igdoura; Nabil G Seidah; Richard C Austin
Journal:  Kidney360       Date:  2022-04-27

Review 4.  PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.

Authors:  Natalie Arnold; Wolfgang Koenig
Journal:  Curr Cardiol Rep       Date:  2022-09-10       Impact factor: 3.955

5.  Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.

Authors:  Vittoria Cammisotto; Francesco Baratta; Valentina Castellani; Simona Bartimoccia; Cristina Nocella; Laura D'Erasmo; Nicholas Cocomello; Cristina Barale; Roberto Scicali; Antonino Di Pino; Salvatore Piro; Maria Del Ben; Marcello Arca; Isabella Russo; Francesco Purrello; Roberto Carnevale; Francesco Violi; Daniele Pastori; Pasquale Pignatelli
Journal:  Int J Mol Sci       Date:  2021-07-03       Impact factor: 5.923

6.  Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels.

Authors:  Chuantao Jiang; Hersharan Nischal; Hua Sun; Li Li; Ying Cao; Peng Wei; Jui-Yoa Chang; Ba-Bie Teng
Journal:  Int J Mol Sci       Date:  2018-02-24       Impact factor: 5.923

7.  Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.

Authors:  Harold E Bays; Robert S Rosenson; Marie T Baccara-Dinet; Michael J Louie; Desmond Thompson; G Kees Hovingh
Journal:  Cardiovasc Drugs Ther       Date:  2018-04       Impact factor: 3.727

8.  Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice.

Authors:  Paul F Lebeau; Jae Hyun Byun; Khrystyna Platko; Ali A Al-Hashimi; Šárka Lhoták; Melissa E MacDonald; Aurora Mejia-Benitez; Annik Prat; Suleiman A Igdoura; Bernardo Trigatti; Kenneth N Maclean; Nabil G Seidah; Richard C Austin
Journal:  JHEP Rep       Date:  2019-11-05

9.  Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.

Authors:  Carlota Oleaga; Michael D Shapiro; Joshua Hay; Paul A Mueller; Joshua Miles; Cecilia Huang; Emily Friz; Hagai Tavori; Peter P Toth; Cezary Wójcik; Bruce A Warden; Jonathan Q Purnell; P Barton Duell; Nathalie Pamir; Sergio Fazio
Journal:  J Am Coll Cardiol       Date:  2021-10-05       Impact factor: 24.094

10.  Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol.

Authors:  Bruce A Warden; Joshua R Miles; Carlota Oleaga; Om P Ganda; P Barton Duell; Jonathan Q Purnell; Michael D Shapiro; Sergio Fazio
Journal:  Am J Prev Cardiol       Date:  2020-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.